These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
513 related articles for article (PubMed ID: 33930416)
41. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Saravolatz LD; Pawlak J; Johnson LB Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274 [TBL] [Abstract][Full Text] [Related]
46. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections. Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316 [TBL] [Abstract][Full Text] [Related]
47. Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen. Bal AM; David MZ; Garau J; Gottlieb T; Mazzei T; Scaglione F; Tattevin P; Gould IM J Glob Antimicrob Resist; 2017 Sep; 10():295-303. PubMed ID: 28732783 [TBL] [Abstract][Full Text] [Related]
48. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. Smith JR; Yim J; Raut A; Rybak MJ Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159 [TBL] [Abstract][Full Text] [Related]
50. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. Hodille E; Delouere L; Bouveyron C; Meugnier H; Bes M; Tristan A; Laurent F; Vandenesch F; Lina G; Dumitrescu O Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079 [TBL] [Abstract][Full Text] [Related]
51. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935 [TBL] [Abstract][Full Text] [Related]
52. Multidrug and vancomycin resistance among clinical isolates of Olufunmiso O; Tolulope I; Roger C Afr Health Sci; 2017 Sep; 17(3):797-807. PubMed ID: 29085408 [TBL] [Abstract][Full Text] [Related]
53. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Stein GE; Wells EM Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750 [TBL] [Abstract][Full Text] [Related]
55. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169 [TBL] [Abstract][Full Text] [Related]
56. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Appelbaum PC Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():16-23. PubMed ID: 16445720 [TBL] [Abstract][Full Text] [Related]
57. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. Tiwari HK; Sen MR BMC Infect Dis; 2006 Oct; 6():156. PubMed ID: 17067393 [TBL] [Abstract][Full Text] [Related]
58. Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals. Alfouzan W; Boswihi SS; Dhar R; Udo E J Infect Public Health; 2020 Oct; 13(10):1589-1591. PubMed ID: 32859552 [TBL] [Abstract][Full Text] [Related]
59. Guzek A; Rybicki Z; Tomaszewski D Indian J Med Microbiol; 2018; 36(1):119-120. PubMed ID: 29735840 [TBL] [Abstract][Full Text] [Related]
60. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Appelbaum PC Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]